Balyasny Asset Management
SQZ

Balyasny Asset Management’s SQZ Biotechnologies Company SQZ Stock Holding History

Balyasny Asset Management’s Portfolio SQZ Stock Details SQZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-12,404
Closed -$28K – 3376
2022
Q3 		$28K Buy
+12,404
New +$37.2K ﹤0.01% 2541

Other funds holding SQZ

Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RC
RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return

Balyasny Asset Management's SQZ Position: Q4 2022 in Review

Balyasny Asset Management sold out of SQZ Biotechnologies Company (SQZ) in Q4 2022, closing a stake of 12,404 shares — an estimated $28K sold.

Balyasny Asset Management first reported a position in SQZ in Q3 2022 and held it in 1 quarter. The position peaked at $28K in Q3 2022. 36 funds tracked by Wall St. Rank hold SQZ as of Q4 2022.

  • Balyasny Asset Management reported no remaining SQZ Biotechnologies Company position as of Q4 2022 after selling out during the quarter.
  • Balyasny Asset Management sold 12,404 SQZ Biotechnologies Company shares in Q4 2022, an estimated $28K.
  • Balyasny Asset Management first reported a position in SQZ Biotechnologies Company in Q3 2022 and held it in 1 quarter.
  • Balyasny Asset Management's SQZ Biotechnologies Company position peaked at $28K in Q3 2022.
  • 36 funds tracked by Wall St. Rank held SQZ Biotechnologies Company as of Q4 2022.

Based on Balyasny Asset Management's 13F filing for Q4 2022, filed 14 Feb 2023.